Zimmer Biomet

Exactech Names New Chief Financial Officer

Retrieved on: 
Tuesday, October 4, 2022

Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, has appointed Tony Collins as its new Chief Financial Officer (CFO).

Key Points: 
  • Exactech , a developer and producer of innovative implants, instrumentation, and smart technologies for joint replacement surgery, has appointed Tony Collins as its new Chief Financial Officer (CFO).
  • View the full release here: https://www.businesswire.com/news/home/20221004005692/en/
    Tony Collins Appointed New Chief Financial Officer of Exactech (Photo: Business Wire)
    Collins joins Exactech from Xenter, Inc., a medical device and data start-up, where he was also CFO.
  • Prior to Xenter, he had an 11-year career at Zimmer Biomet, where his last role was as Group Chief Financial Officer with responsibility for strategic and financial planning, business development, accounting, and internal controls for the companys global business units.
  • He also held several executive leadership positions with Guidant/Boston Scientific, including Chief Financial Officer of Guidant Japan.

World Renowned Medical Pioneer, Inventor, Mentor, 94 Year-Old Orthopaedic Surgeon William H. Harris, MD, Receives Lifetime Achievement Award

Retrieved on: 
Thursday, September 29, 2022

Harris, MD, (pictured at far right)Founder and Director Emeritus of the Massachusetts General Hospital ,Harris Orthopaedics Laboratory.

Key Points: 
  • Harris, MD, (pictured at far right)Founder and Director Emeritus of the Massachusetts General Hospital ,Harris Orthopaedics Laboratory.
  • (Picturedsecond from left) is Orthopaedic Surgeon Kevin D. Plancher, MD, MPH, Founder of OSET and Ivan Tornos, President & COO of Zimmer Biomet (pictured third from left).
  • His laboratory helped unravel a totally new, destructive disease damaging total hip and total knee reconstruction.
  • Orthopaedic Summit Evolving Techniques (OSET) is a 501c3 organization founded by Orthopaedic Surgeon, Kevin D. Plancher, MD, MPH, FAOA, FAAOS, FACS, and Conference Chair, Brian D Busconi, MD of UMASS Medical Center in 2010.

Orthopedic Biomaterials Global Markets Report 2022: Focus on Ceramics & Bioactive Glasses; Calcium Phosphate Cements; Polymers; Metal; Composites - ResearchAndMarkets.com

Retrieved on: 
Thursday, September 29, 2022

The orthopedic biomaterials market comprises revenue generated by establishments from the manufacturing and sales of orthopedic biomaterials.

Key Points: 
  • The orthopedic biomaterials market comprises revenue generated by establishments from the manufacturing and sales of orthopedic biomaterials.
  • The orthopedic biomaterials market covered in this report is segmented by material type into ceramics and bioactive glasses, calcium phosphate cement, polymers, metal, and composites.
  • Polymers are used as orthopedic biomaterials intended to be inserted into the human body as constituents.
  • 3D printing of orthopedic implants is one of the recent developments in the orthopedic biomaterials market.

DeepIntent's Chris Paquette Named CEO of the Year in 2022 PM360 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ --PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries, recently named Chris Paquette a CEO of the Year in its annual Trailblazer Awards.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ --PM360, a publication for marketing decision makers in the pharmaceutical, biotech, diagnostics, and medical device industries, recently named Chris Paquette a CEO of the Year in its annual Trailblazer Awards.
  • That year, CEO Chris Paquette was named to the PM360 ELITE list in the Entrepreneur category and selected as the publication's 2020 Trailblazer Vanguard Award winner.
  • "I founded DeepIntent on the idea that technology can measurably improve the lives of patients," said Chris Paquette, CEO, DeepIntent.
  • Since 2009, the PM360 Trailblazer Awards have recognized outstanding achievement and innovation in healthcare marketing.

PM360 Magazine Announces Winners of 2022 Trailblazer Awards

Retrieved on: 
Friday, September 23, 2022

NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022. The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries. In total, 72 winners were named across eight overall categories: Companies of the Year, CEOs of the Year, Products of the Year, Marketer of the Year, Marketing Team of the Year, Lifetime Achievement, Brand Champions, and Initiatives.

Key Points: 
  • NEW YORK, Sept. 23, 2022 /PRNewswire/ -- PM360, a leading life sciences marketing industry trade publication, announced the winners of their 14th annual Trailblazer Awards during an event held at Gotham Hall in New York City on Thursday, September 22, 2022.
  • The awards recognize outstanding companies, CEOs, products, marketers, brand managers, and cutting-edge initiatives within the pharmaceutical, biotech, medical device, and diagnostics industries.
  • Each of the winners were judged and selected by the PM360 Editorial Advisory Board, a cross section of experts from across the industry.
  • PM360 will publish profiles of this year's Trailblazer winners in its October issue and on its website.

Pulse Biosciences Announces Strategic Change of Focus in Support of Significant Additional Opportunities for medicinal related Nano-Pulse Stimulation

Retrieved on: 
Tuesday, September 20, 2022

I am confident in NPS technology and its potential, said Robert Duggan, Executive Chairman of Pulse Biosciences.

Key Points: 
  • I am confident in NPS technology and its potential, said Robert Duggan, Executive Chairman of Pulse Biosciences.
  • Implementing the present time strategic opportunities does not require the significant sales, marketing and related administrative support team that has been in place.
  • Accordingly, headcount now stands at 66 employees principally focused on engineering, business development and related new product support personnel.
  • Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in the United States and other countries.

Zimmer Biomet Receives FDA Clearance for Identity™ Shoulder System for Shoulder Replacement

Retrieved on: 
Tuesday, September 20, 2022

WARSAW, Ind., Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for anatomic, reverse and revision shoulder replacement.

Key Points: 
  • WARSAW, Ind., Sept. 20, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Identity Shoulder System for anatomic, reverse and revision shoulder replacement.
  • The latest addition to Zimmer Biomet's portfolio of shoulder replacement systems, the Identity Shoulder System is designed to allow surgeons to devise and execute a patient-specific surgical plan with precision.
  • "The FDA clearance of the Identity Shoulder System is exciting because it offers surgeons a highly adaptable solution for anatomic, reverse and revision procedures to help patients optimize natural shoulder movement," said Ivan Tornos, Chief Operating Officer at Zimmer Biomet.
  • This new system expands Zimmer Biomet's upper extremities portfolio, which includes the Comprehensive Nano Stemless Shoulder and the Signature ONE Surgical Planning System, part of the ZBEdge Shoulder ecosystem.

Zimmer Biomet and Surgical Planning Associates Announce Exclusive Multi-Year Co-Marketing Agreement for HipInsight™ Mixed Reality System for Total Hip Replacement

Retrieved on: 
Thursday, September 1, 2022

WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.

Key Points: 
  • WARSAW, Ind., Sept. 1, 2022 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced an exclusive, multi-year co-marketing agreement with Surgical Planning Associates, Inc. to commercialize HipInsight, the first FDA-cleared mixed reality navigation system for total hip replacement.
  • "This collaboration enables us to offer surgeons a sophisticated and proven mixed reality-based visualization tool customized for exclusive use with our hip implant portfolio."
  • "We're proud to partner with Zimmer Biomet, a leader in joint arthroplasty, to co-market HipInsight for their portfolio of hip implant systems," said Stephen B. Murphy, M.D., founder of Surgical Planning Associates.
  • A pioneer in the fields of surgical planning and computer-assisted joint reconstruction, SPA is privately held and based in Boston.

ZimVie to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference

Retrieved on: 
Monday, August 29, 2022

WESTMINSTER, Colo., Aug. 29, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will participate in Morgan Stanleys 20th Annual Global Healthcare Conference held in New York, New York.

Key Points: 
  • WESTMINSTER, Colo., Aug. 29, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will participate in Morgan Stanleys 20th Annual Global Healthcare Conference held in New York, New York.
  • Vafa Jamali, President and Chief Executive Officer, and Rich Heppenstall, Chief Financial Officer, are scheduled to present onTuesday, September 13th at 7:20 AM EDT.
  • Interested parties may access a live and archived version of the webcast of the presentation at: https://investor.zimvie.com/events-presentations/event-calendar .
  • Follow @ZimVie on Twitter , Facebook , LinkedIn , or Instagram .

Orthopedic Biomaterials Market Revenue to Surpass USD 32.2 Billion by 2030, says P&S Intelligence

Retrieved on: 
Monday, August 22, 2022

Moreover, the improved biomaterials being offered by companies have raised the success rates of operations, encouraging more patients to go for them.

Key Points: 
  • Moreover, the improved biomaterials being offered by companies have raised the success rates of operations, encouraging more patients to go for them.
  • Get the sample pages of this report: https://www.psmarketresearch.com/market-analysis/orthopedic-biomaterials...
    Non-metallic biomaterials are more popular in orthopedics, generating almost 60% of the market revenue in 2021.
  • Hospitals & clinics are the larger end users in the orthopedic biomaterials market, with an over 40% share.
  • Moreover, almost all major market players operate in the continent, which makes advanced orthopedic biomaterials easily available.